Prothena to Host Update on PRX003 Phase 2 Development

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Prothena to Host Update on PRX003 Phase 2 Development Strategy

DUBLIN, Ireland, Sept. 22, 2016 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ: PRTA ), a late-stage clinical biotechnology company focused on the discovery, development, and commercialization of novel protein immunotherapies, today announced that members of its management team will discuss the Phase 2 development strategy for PRX003, the antibody in development for the potential treatment of inflammatory diseases, including psoriasis, during a webcast on September 29. 

Conference Call and Webcast Details

Prothena management will provide an overview of PRX003, a novel antibody that targets CD146 (or melanoma cell adhesion molecule, MCAM) and discuss its Phase 2 development strategy during a live audio webcast and conference call on September 29, 2016, at 4:30 PM EDT. The webcast and slide presentation will be made available on the company's website at www.prothena.com under the Investors tab in the Events and Presentations section.

To access the conference call via dial-in, please dial (877) 887-5215  (U.S. toll free) or (315) 625-3069 (international) five minutes prior to the start time and refer to conference ID number 83102616. A replay of the webcast and call will be available for at least 90 days via dial-in at (855) 859-2056 (U.S. toll free) or (404) 537-3406 (international), Conference ID Number 83102616.

About Prothena

Prothena Corporation plc is a global, late-stage clinical biotechnology company seeking to fundamentally change the course of progressive diseases with its clinical pipeline of novel therapeutic antibodies. Fueled by its deep scientific understanding built over decades of research in protein misfolding and cell adhesion — the root causes of many serious or currently untreatable amyloid and inflammatory diseases — Prothena has advanced several drug candidates into clinical trials while pursuing discovery of additional novel therapies. Our pipeline of antibody-based product candidates targets a number of potential indications including AL amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), inflammatory diseases, including psoriasis (PRX003), and ATTR amyloidosis (PRX004). For more information, please visit the company's web site at www.prothena.com .

Contacts Investors: Tran Nguyen, CFO 650-837-8535, IR@prothena.com Media: Ellen Rose 650-922-2405, ellen.rose@prothena.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Gong, Agentforce, Avoma Crowned 2026 CI Champions

Updated Category News Views 22

Diving Deep into Conversation Intelligence There's a lot to unpack when three software titans hog the spotlight, and that's exactly what's happening in the world of conversation intelligence this year. It's like we've hit the jackpot with Gong, Agentforce Sales, and Avoma carving out their turf as the 2026 Champions, according to the venerable Info-Tech Research Group....

Continue Reading
EMCO's New Automated Facility Could Shake Industry

Updated Category News Views 20

A Novel Leap in Production Capacity EMCO Industries just put a solid foot on the accelerator with their brand-new, shiny, fully automated plant over in Claremore, Oklahoma. If you're glancing at heavy-duty trailer springs, you can't ignore the fact that this is a multimillion-dollar investment. Heck, this monstrous 30,000-square-foot facility more than doubles what EMCO...

Continue Reading
HelloNation Brings 'Edvertising' to NC REALTORS® Event

Updated Category News Views 23

HelloNation's Bold Step into Real Estate Networking October 8th to the 11th is shaping up to be a pivotal few days in Wilmington, North Carolina. Here’s the scoop: HelloNation, known for its innovative 'edvertising' model, is joining the bustling crowd at the 2026 NC REALTORS® Convention. This isn’t just any get-together—it's the grandest annual jamboree for real...

Continue Reading
OCI N.V. Secures a Win in Court; EGM Proceeds as Planned

Updated Category News Views 24

OCI Dodges a Bullet in Amsterdam Court Stepping into the courtroom drama, OCI N.V. just took home a win as the Amsterdam Court of Appeal's Enterprise Chamber gave them a clean bill of health, kicking out the inquiry request from VEB and a bunch of other shareholders. The judges weren't convinced there was anything fishy going on, so they tossed the inquiry petition and...

Continue Reading
Ornellaia's 2026 Harvest: Adapting to Nature's Whims

Updated Category News Views 13

A Year Marked by Weather's Unpredictable Dance Nobody said making wine was a walk in the park, and the folks at Ornellaia know better than most how to roll with whatever nature throws their way. The 2026 harvest story is as much about unlocking the secrets of the soil as it is about navigating the quirks of the weather. Situated in Bolgheri, Italy, this year's vintage...

Continue Reading
Wally Disrupts Dental Industry with $25M Funding

Updated Category News Views 24

A New Breath of Fresh Air for Dental Care Dental visits—a tedious, costly affair we've all dreaded. So, when Wally rolls out an overhaul in this stale landscape, it's worth taking notice. With $25 million in their pockets from Series A funding led by Maveron, Wally's swaggering in with a plan to flip the script on dental care across the nation. Redefining the Dental...

Continue Reading
Merit Expands in New York with Bold Acquisition Move

Updated Category News Views 20

Merit Financial's Growth Trajectory Takes a Leap You watch the movers and shakers in this game long enough, and you start to see patterns. Merit Financial Advisors is one of those juggernauts you'd better keep an eye on. These folks just scooped up Moldenhauer & Associates—a firm that's been a staple in Orchard Park, New York—for a cool $1.1 billion worth of client...

Continue Reading
Vitamin Angels Drives Global Nutrition Advancements

Updated Category News Views 17

Navigating the Waters of Global Nutrition Bet you never thought a vitamin program could spearhead the front lines of healthcare, huh? Vitamin Angels are grinding away under the radar, shifting the landscape for maternal and child nutrition. At the heart of it all is their vision to make UNIMMAP multiple micronutrient supplementation (MMS) a staple in the global playbook....

Continue Reading
Decoding CarBravo-Certified vs Traditional Used Cars

Updated Category News Views 18

What’s Behind Door Number One: CarBravo Certification When you walk onto a car lot these days, it's a mixed bag: shiny badges boasting certifications or basic used car signage. For anyone who's spent time around cars, two types stick out—there’s your CarBravo-certified vehicles and your good ol' used cars. Now, Marissa McCoy and Jill Maniaci from Heidebreicht...

Continue Reading
Duke Energy's Cost-Protection Plan Shields Ratepayers

Updated Category News Views 17

Shielding Customers From Data Center Costs Let's get right into the thick of it: Duke Energy's latest move is a strategic one, shrouded in industry terms but with a real impact on regular folks' wallets. The company's agreement with heavyweights like Amazon, Google, and Meta aims to protect existing customers in North Carolina from getting hit with the costs of powering...

Continue Reading

Top 5 Most Recently Viewed Articles

Taitron's Strategic Shift: Nasdaq Delisting and Financial Update

Updated Category News Views 251

Overview of Taitron's Recent Developments Taitron Components Incorporated (NASDAQ: TAIT) recently made headlines by announcing its voluntary delisting from The Nasdaq Stock Market. The company's decision came as it recognized that the cost of maintaining its Nasdaq listing outweighed the benefits for its shareholders. Reasons Behind the Delisting The board concluded that...

Continue Reading
Merck's Two-Drug HIV Treatment Achieves Trial Success

Updated Category News Views 130

Merck's Groundbreaking Two-Drug Regimen for HIV Treatment Recently, Merck & Co Inc (NYSE: MRK) announced promising results from two important Phase 3 clinical trials. This involved their investigational two-drug regimen combining doravirine and islatravir (DOR/ISL) aimed at treating adults living with HIV-1 infection. Key Findings from the Trials The trials were designed...

Continue Reading
Immunic’s Patent Milestone for Vidofludimus Calcium in MS

Updated Category News Views 230

Immunic Achieves Patent Allowance for Vidofludimus Calcium Immunic, Inc. (Nasdaq: IMUX), a leading biotechnology firm, has recently marked a significant milestone by receiving a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for its patent application focused on the use of vidofludimus calcium, particularly in the treatment of progressive...

Continue Reading
Creatd, Inc. Advances with OTCQB Approval and Strong Equity

Updated Category News Views 148

Creatd, Inc. Takes a Significant Step with OTCQB Approval Creatd, Inc. (OTC: CRTD) has reached a significant milestone by being approved to trade on the OTCQB Venture Market. This remarkable achievement showcases the company's dedication and progress towards enhancing its market presence. Starting from a pivotal date, Creatd will now be traded on a more recognized...

Continue Reading
KROMATID Unveils Groundbreaking KROMASURE PinPoint Technology

Updated Category News Views 155

KROMATID Launches KROMASURE PinPoint for Enhanced Genomic Analysis With an aim to transform gene therapy development, KROMATID has unveiled its innovative KROMASURE PinPoint system. This next-generation platform revolutionizes transgene integration analysis by providing single-cell resolution that was previously unattainable. Researchers now have the ability to detect...

Continue Reading